Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group.

@article{Greene1999EffectOA,
  title={Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group.},
  author={Douglas A. Greene and Joseph C. Arezzo and Morton B. Brown},
  journal={Neurology},
  year={1999},
  volume={53 3},
  pages={580-91}
}
OBJECTIVE To determine whether the aldose reductase inhibitor (ARI) zenarestat improves nerve conduction velocity (NCV) and nerve morphology in diabetic peripheral polyneuropathy (DPN). METHODS A 52-week, randomized, placebo-controlled, double-blinded, multiple-dose, clinical trial with the ARI zenarestat was conducted in patients with mild to moderate DPN. NCV was measured at baseline and study end. Contralateral sural nerve biopsies were obtained at 6 weeks and at the study's end for nerve… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 94 extracted citations

Similar Papers

Loading similar papers…